Table 2 Features of JDM patients who reported flare of underlying disease post COVID-19 (n = 4; all were female, white, and non-Hispanic)
From: The impact of the COVID-19 pandemic on patients with juvenile idiopathic inflammatory myopathies
Age group (years) | Disease duration (years) | MSA | Baseline medication | COVID vaccine | Patient GAS prior to COVID-19 | Patient GAS post COVID-19 | COVID-19 positive more than once | Meds held for COVID-19 (days) |
|---|---|---|---|---|---|---|---|---|
6–10 | 7.96 | MJ | MTX, HCQ, IVIG | no | 2 | 8 | Yes, Milder 2nd time | Yes (7 days) |
11–14 | 2.05 | Unknown | Steroids, MTX, HCQ, IVIG, MMF | no | 3 | 6 | Yes, Milder 2nd time | Yes (14 days) |
18–21 | 9.9 | p155/140 | HCQ, IVIG, Orencia | yes | 3 | 5 | No | Yes (14 days) |
19–21 | 1.51 | MDA-5 | None | yes | 1 | 9 | Yes, diagnosed after first episode | No |